CERO Therapeutics Holdings, Inc. announced on March 13, 2025, the presentation of encouraging preclinical results for its lead compound, CER-1236, in ovarian cancer. The data was presented during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors meeting in San Diego.
The poster, titled 'TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,' demonstrated that CER-1236 treated ovarian cancer cells effectively. Importantly, the compound did not generate toxicity in animal models (mice).
Investigators observed T cell engraftment in lymphoid organs after CER-1236 infusion, with no in-life observations, clinical pathology, or histopathological evaluations indicating toxicity. These findings continue to build the company's data wealth, highlighting CER-1236’s efficacy on cancer cells while maintaining a favorable safety profile, and suggest broad utility across cancer types.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.